Fresenius Medical Care AG & Co. KGaA

  • WKN: 578580
  • ISIN: DE0005785802
  • Land: Deutschland

Nachricht vom 04.11.2019 | 11:17

Fresenius Medical Care AG & Co. KGaA: Release of a capital market information

Fresenius Medical Care AG & Co. KGaA / Announcement pursuant to Art. 5 para. 1 lit. b), para. 3 of Regulation (EU) No 596/2014 and Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052

04.11.2019 / 11:17
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


- Share buy-back - 20th Interim Report

In the period from October 28, 2019 until and including November 1, 2019, a total of 81,721 shares were repurchased within the framework of the share buy-back programme of Fresenius Medical Care AG & Co. KGaA ('Fresenius Medical Care') announced on June 14, 2019 pursuant to Art. 5 para. 1 lit. a) of Regulation (EU) No 596/2014 and Art. 2 para. 1 of Delegated Regulation (EU) 2016/1052.

The purchase was carried out exclusively by a credit institution commissioned by Fresenius Medical Care via the XETRA trading platform on the Frankfurt Stock Exchange:

Day of repurchase Aggregated volume in number of shares Weighted average share price
in EUR
28.10.2019 - -
29.10.2019 - -
30.10.2019 - -
31.10.2019 44,897 EUR 2,902,800.72
01.11.2019 36,824 EUR 2,425,259.20
 

The total volume of shares repurchased within the framework of this share buy-back in the period from June 17, 2019 until and including November 1, 2019 therefore amounts to 3,726,735 shares.

Detailed information on the transactions pursuant to Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052 is available on Fresenius Medical Care's website at www.freseniusmedicalcare.com under section Investors.

Fresenius Medical Care AG & Co. KGaA
represented by Fresenius Medical Care Management AG
represented by its Management Board

Bad Homburg v.d.H., November 4, 2019



04.11.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Munich Re beschließt Aktienrückkauf

26. Februar 2020, 13:17

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

26. Februar 2020